CLINICAL IMMUNOLOGY
Single antigen flow beads for identification of human leukocyte antigen antibody specificities in hypersensitized patients with chronic renal failure
Submission date: 2015-05-18
Final revision date: 2015-07-09
Acceptance date: 2015-07-20
Publication date: 2016-01-20
Cent Eur J Immunol 2016;41(1):93-100
KEYWORDS
ABSTRACT
Aims of this study were to identify class I and class II antibodies in highly sensitized patients by flow cytometry single antigen bead (FC-SAB) assay and to evaluate according to donor HLA type in order to increase their kidney transplantation chance.
Material and methods: We analyzed 60 hypersensitive patients of 351 individuals, who applied to our laboratory for PRA test in November 2013-December 2014. Flow cytometric PRA screening and single antigen bead commercial kits were used for these analyses.
Results: In our study group, 19 (31.7%) of these patients were male while 41 (68.3%) patients were female. The most common acceptable antigens were A*02 (10.11%), HLA-A*23 (10.11%), HLA-B*38 (8.79%) and HLA-DRB1*03 (7.83%) in hypersensitive patients. The highest antibody reactivity on SAB was observed against HLA-A*25, HLA-B*45, HLA-DRB1*04 and HLA-DRB1*08 antigens.
Conclusions: The determination of these acceptable and unacceptable antigens may increase their transplantation chance. Pre-transplant HLA antibody identifications provide prognostic information with respect to the determination of patients who are at increased risk of graft loss.
Material and methods: We analyzed 60 hypersensitive patients of 351 individuals, who applied to our laboratory for PRA test in November 2013-December 2014. Flow cytometric PRA screening and single antigen bead commercial kits were used for these analyses.
Results: In our study group, 19 (31.7%) of these patients were male while 41 (68.3%) patients were female. The most common acceptable antigens were A*02 (10.11%), HLA-A*23 (10.11%), HLA-B*38 (8.79%) and HLA-DRB1*03 (7.83%) in hypersensitive patients. The highest antibody reactivity on SAB was observed against HLA-A*25, HLA-B*45, HLA-DRB1*04 and HLA-DRB1*08 antigens.
Conclusions: The determination of these acceptable and unacceptable antigens may increase their transplantation chance. Pre-transplant HLA antibody identifications provide prognostic information with respect to the determination of patients who are at increased risk of graft loss.
REFERENCES (18)
1.
Vaidya S, Partlow D, Susskind B, et al. (2006): Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay. Transplantation 82: 1524-1528.
2.
Doxiadis II, Duquesnoy RJ, Claas FH (2005): Extending options for highly sensitized patients to receive a suitable kidney graft. Curr Opin Immunol 17: 536-540.
3.
Bray RA, Nolen JD, Larsen C, et al. (2006): Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 6: 2307-2315.
4.
Patel R, Terasaki PI (1969): Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280: 735-739.
5.
Lefaucheur C, Loupy A, Hill GS, et al. (2010): Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 21: 1398-1406.
6.
Amico P, Hönger G, Mayr M, et al. (2009): Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 87: 1681-1688.
7.
Gebel HM, Bray RA, Nickerson P (2003): Pre-transplant assessment of donor reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 3: 1488-1500.
8.
Pei R, Lee JH, Shih NJ, et al. (2003): Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specifities. Transplantation 75: 43-49.
9.
Bielmann D, Hönger G, Lutz D, et al. (2007): Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 7: 626-632.
10.
Stegall MD, Gloor J, Winters JL, et al. (2006): A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6: 346-351.
11.
Akalin E, Ames S, Sehgal V, et al. (2005): Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation 79: 742.
12.
Duquesnoy RJ, Witvliet M, Doxiadis II, et al. (2004): HLA Matchmaker-based strategy to identify acceptable HLA class I mismatches for highly sensitized kidney transplant candidates. Transpl Int 17: 22-30.
13.
Dieplinger G, Ditt V, Arns W, et al. (2014): Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations. Transpl Int 27: 60-68.
14.
Claas FH, Doxiadis II (2009): Management of the highly sensitized patient. Curr Opin Immunol 21: 569-572.
15.
Gandhi MJ, Degoey S, Falbo D, et al. (2013): Inter and intra laboratory concordance of HLA antibody results obtained by single antigen bead based assay. Hum Immunol 74: 310-317.
16.
Claas FH, Witvliet MD, Duquesnoy RJ, et al. (2004): The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft survival. Transplantation 78: 190-193.
17.
Jackson AM, Zachary AA (2008): The problem of transplanting the sensitized patients: whose problem is it? Front Biosci 13: 1396-1412.
18.
Claas FH, Rahmel A, Doxiadis II (2009): Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 88: 447-452.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
